Clinical Trial Update: A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing camrelizumab as adjuvant therapy for resectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN